newsfilter
← Latest News
Business Wire·

Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme

A
  • Agilent Technologies Inc. announced the SureSelect Cancer Research Pan Heme, a hybrid capture-based NGS solution for comprehensive genomic profiling of hematologic malignancies.
  • The solution was developed in collaboration with experts at Roswell Park Comprehensive Cancer Center to integrate DNA & RNA profiling, automated sample preparation, & bioinformatics.
  • SureSelect Cancer Research Pan Heme interrogates 359 DNA genes & 124 RNA genes to assess SNVs, indels, CNVs, IGH/IGK/IGL translocations, & gene fusions.
  • The panel expands Agilent's tumor profiling portfolio alongside SureSelect Cancer Research CGP for solid tumors & SureSelect Human All Exon V8 for ultra-comprehensive research.
  • Majken Nielsen, vice president of Agilent's Clinical Diagnostics Division, stated the solution reduces hands-on demands while generating deeper molecular insights.
  • Sean Glenn, Ph.D., vice chair of molecular pathology at Roswell Park, noted the workflow provides a comprehensive view of complex hematologic malignancies in approximately 48 hours.
  • The system can be paired with the Agilent Magnis NGS Prep System for fully automated library preparation using prefilled, cartridge-based reagents.
  • QIAGEN Clinical Insight (QCI) supports variant analysis & reporting, with manual & semiautomated configurations also available.
  • SureSelect Cancer Research Pan Heme is designated For Research Use Only & is not for use in diagnostic procedures.
  • Agilent Technologies generated $6.95 billion in revenue in fiscal year 2025 & employs approximately 18,000 people worldwide.